MAKALELER


SCI, SSCI ve AHCI tarafından taranan dergilerde yayımlanmış veya kabul edilmiş makaleler

Uluslararası
  • A.Kıpçak , S.Sezan , Ö.Karpat , E.Kaya , S.Baylan , E.Sarıyar , C.Yandım and Z.Fırtına Karagonlar.
    (2024) Suppression of CTC1 inhibits hepatocellular carcinoma cell growth and enhances RHPS4 cytotoxicity.
    Molecular Biology Reports , Vol. 51, No. 1, 799-799,
  • S.Uyulgan , S.N.Köse , A.Kıpçak , Y.Başkan , G.Dağlar , Z.Fırtına Karagonlar , C.Yandım.
    (2024) Thyroid hormone T3 augments the cytotoxicity of sorafenib in Huh7 hepatocellular carcinoma cells by suppressing AKT expression.
    Journal Of Cancer Research And Therapeutics , Vol. 20, No. 3, 755-762,
  • S.N.Köse , T.Yaraş , A.Bursalı , Y.Oktay , C.Yandım , G.Karakülah.
    (2024) Expressions of the satellite repeat HSAT5 and transposable elements are implicated in disease progression and survival in glioma.
    Turkish Journal Of Biology , Vol. 48, No. 4, 242-256,
  • N.Keske , B.Özay , E.Y.Tükel , M.Menteş , C.Yandım.
    (2023) In silico drug screen reveals potential competitive MTHFR inhibitors for clinical repurposing.
    Journal Of Biomolecular Structure And Dynamics , Vol. 41, No. 21, 11818-11831,
  • M.Menteş , C.Yandım.
    (2023) Identification of PPA1 inhibitor candidates for potential repurposing in cancer medicine.
    Journal Of Cellular Biochemistry , Vol. 10, No. 124, 1646-1663,
  • A.Atik , T.Günal , P.Acar Bozkurt , S.N.Köse , B.Alp , C.Yandım , N.M.Kaleli , G.Kabay and G.Kaleli.
    (2023) Characterization of cisplatin loaded hydrophilic glycol chitosan modified eumelanin nanoparticles for potential controlled-release application.
    Journal Of Drug Delivery Science And Technology , Vol. Vol 18, No. 104440,
  • C.Yandım , G.Karakülah.
    (2022) Repeat expression is linked to patient survival and exhibits single nucleotide variation in pancreatic cancer revealing LTR70:r.879A>G.
    Gene , Vol. 622, No. 146344,
  • M.Menteş , B.Karakuzulu , G.Uçar , C.Yandım.
    (2022) Comparative molecular dynamics analyses on PIK3CA hotspot mutations with PI3Kα specific inhibitors and ATP.
    Computational Biology And Chemistry , Vol. 99, No. 107726,
  • G.Karakülah , C.Yandım.
    (2021) Identification of differentially expressed genomic repeats in primary hepatocellular carcinoma and their potential links to biological processes and survival.
    Turkish Journal Of Biology , Vol. 45, No. 5, 599-612,
  • G.Karakülah , C.Yandım.
    (2020) Signature changes in the expressions of protein-coding genes, lncRNAs and repeat elements in early and late cellular senescence.
    Turkish Journal Of Biology , Vol. 44 , No. 6, 356-370,
  • E.Kostaras , T.Kaserer , G.Lazaro , S.Heuss , A.Hussain , P.Casado , A.Hayes , C.Yandım , N.Palaskas , Y.Yu , B.Schwartz , F.Raynaud , Y.Chung , P.Cutillas and I.Vivanco.
    (2020) A systematic molecular and pharmacologic evaluation of AKT inhibitors reveals new insight into their biological activity.
    British Journal Of Cancer , Vol. 123, No. 4, 542-555,
  • C.Yandım , G.Karakülah.
    (2019) Dysregulated expression of repetitive DNA in ER+/HER2- breast cancer.
    Cancer Genetics , Vol. 239, 36-45,
  • G.Karakülah , N.Arslan , C.Yandım , A.Suner.
    (2019) TEffectR: an R package for studying the potential effects of transposable elements on gene expression with linear regression model.
    PeerJ , No. 7:e8192,
  • C.Yandım , G.Karakülah.
    (2019) Expression dynamics of repetitive DNA in early human embryonic development.
    BMC Genomics , No. 20,
  • T.Natisvili , C.Yandim , R.Silva , G.Emanuelli , F.Krueger , S.Nageshwaran , R.Festenstein.
    (2016) Transcriptional activation of pericentromeric satellite repeats and disruption of centromeric clustering upon proteasome inhibiton.
    Plos One , Vol. 11, No. 11,
  • V.Libri *(equal) , C.Yandim *(equal) , S.Athanasopoulus , N.Loyse , T.Natisvili , P.Law , P.Chan , T.Mohammad , M.Mauri , K.Tam , J.Leiper , S.Piper , A.Ramesh , M.Parkinson , L.Huson , P.Giunti and R.Festenstein.
    (2014) Epigenetic and neurological effects and safety of high-dose nicotinamide in patients with Friedreichs ataxia: an exploratory, open-label, dose-escalation study.
    The Lancet , Vol. 384, No. 9942, 504-513,
  • P.Chan , R.Torres , C.Yandim , P.Law , S.Khadayate , M.Mauri , C.Grosan , N.Chapman-Rothe , P.Giunti , M.Pook , R.Festenstein.
    (2013) Heterochromatinization induced by GAA-repeat hyperexpansion in Friedreichs ataxia can be reduced upon HDAC inhibition by vitamin B3.
    Human Molecular Genetics , Vol. 22, No. 13, 2662-2675,
  • C.Yandim , T.Natisvili , R.Festenstein.
    (2013) Gene regulation and epigenetics in Friedreichs ataxia.
    Journal Of Neurochemistry , No. 126, 21-42,
  • P.Wijchers , C.Yandim , E.Panousopoulou , M.Ahmad , N.Harker , A.Saveliev , P.Burgoyne , R.Festenstein.
    (2010) Sexual dimorphism in mammalian autosomal gene regulation is determined not only by Sry but by sex chromosome complement as well.
    Developmental Cell , Vol. 19, No. 3, 477-484,